IP Library Granted Patent US 9,044,512
Granted Patent B2
US 9,044,512 · App. 14/325,951 · Granted Jun 2, 2015

Amino alcohol cationic lipids for oligonucleotide delivery

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,044,512
App. No.
14/325,951
Granted
Jun 2, 2015
Kind
B2
Abstract

The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that is more efficacious than traditional cationic lipids. The present invention employs amino alcohols to enhance the efficiency of in vivo delivery of siRNA.

Claims (17)

1. A cationic lipid of Formula A:

wherein:

R 1 and R 2 are independently selected from methyl, ethyl and propyl, wherein said methyl, ethyl and propyl is optionally substituted with one to three substituents selected from R′;

R 3 is selected from H, methyl, ethyl and propyl;

R′ is independently selected from halogen, R″, OR″, SR″, CN, CO 2 R″ and CON(R″) 2 ;

R″ is independently selected from H and (C 1 -C 6 )alkyl, wherein said alkyl is optionally substituted with halogen and OH;

L 1 is selected from C 4 -C 22 alkyl and C 4 -C 22 alkenyl, said alkyl and alkenyl are optionally substituted with R′; and

L 2 is selected from C 4 -C 22 alkyl and C 4 -C 22 alkenyl, said alkyl and alkenyl are optionally substituted with R′;

or any pharmaceutically acceptable salt or stereoisomer thereof.

2. A cationic lipid of Formula A according to claim 1 , wherein:

L 1 is C 4 -C 22 alkenyl.

3. A lipid nanoparticle comprising a cationic lipid according to claim 1 .

4. The lipid nanoparticle of claim 3 , wherein the nanoparticle comprises oligonucleotides.

5. The lipid nanoparticle of claim 4 wherein the oligonucleotides are siRNA or miRNA.

6. The lipid nanoparticle of claim 5 wherein the oligonucleotides are siRNA.

7. The lipid nanoparticle of claim 4 , wherein the lipid nanoparticle comprises cholesterol and PEG-DMG.

8. The lipid nanoparticle of claim 7 , wherein the lipid nanoparticle further comprises DSPC.

Assignments (2)
SECURITY INTEREST Recorded Oct 1, 2025
From: ALNYLAM PHARMACEUTICALS, INC.; SIRNA THERAPEUTICS, INC.
To: BANK OF AMERICA, N.A.
Reel/Frame 072996/0337 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 8, 2015
From: MERCK SHARP & DOHME CORP.
To: SIRNA THERAPEUTICS, INC.
Reel/Frame 034665/0308 →